Effect of topotecan as second-line chemotherapy for small cell lung cancer patients with interstitial lung disease

Journal of Chemotherapy

Volumn 23, Issue 6, 2011, Pages 367-370

  Suzuki, H ^a   Hirashima, T ^a   Kobayashi, M ^a   Sasada, S ^a   Okamoto, N ^a   Uehara, N ^a   Matsuura, Y ^a   Tamiya, M ^a   Morishita, N ^a   Higashiguchi, M ^a   Tsumori, T ^a   Kawase, I ^a  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMRUBICIN; CARBOPLATIN; ETOPOSIDE; IRINOTECAN; TOPOTECAN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG SMALL CELL CANCER; LUNG TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; RELAPSE; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; LUNG TUMOR; MIDDLE AGED;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; TOPOTECAN;

EID: 84864956387     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2011.23.6.367     Document Type: Article

References (15)

1. Turner-Warwick M, Lebowitz M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis and lung cancer. Thorax. 1980;35(7):496-9.
2. Niho S, Goto K, Yoh K, Kim YH, Ohmatsu H, Kubota K, et al. Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs. Jpn J Clin Oncol. 2006;36(5): 269-73.
3. Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med. 2008;177(12): 1348-57.
4. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-16.
5. Spiro SG, Souhami RL, Geddes OM, Ash CM, Quinn H, Harper PG, et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer. 1989;59(4):578-83.
6. Schiller JH, Adak S, Cella O, DeVore RF, 3rd, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage smallcell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(8):2114-22.
7. Takeda K, Negoro S, Sawa T, Nakagawa K, Kawahara M, Isobe T, et al. A phase II study of topotecan in patients with relapsed small-cell lung cancer. Clin Lung Cancer. 2003;4(4):224-8.
8. Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol. 2008;26(33):5401-6.
9. Kurata T, Kashii T, Takeda K, Seki N, Tsuboi M, Kobayashi M, et al. A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial. J Thorac Oncol. 2009;4(5):644-8.
10. Choi HJ, Cho BC, Shin SJ, Cheon SH, Jung JY, Chang J, et al. Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. Cancer Chemother Pharmacol. 2008;61(2):309-13.
11. Kakolyris S, Mavroudis O, Tsavaris N, Souglakos J, Tsiafaki P, Kalbakis K, et al. Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study. Ann Oncol. 2001;12(2):193-7.
12. Neubauer M, Schwartz J, Caracandas J, Conkling P, Ilegbodu O, Tuttle T, et al. Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with Eastern Cooperative Oncology Group Performance Status of 2, or age> or = 70 years. J Clin Oncol. 2004;22(10):1872-7.
13. Groen HJ, Fokkema E, Biesma B, Kwa B, van Putten JW, Postmus PE, et al. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. J Clin Oncol. 1999;17(3):927-32.
14. Giaccone G, Ferrati P, Donadio M, Testore F, Calciati A. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol. 1987; 23(11):1697-9.
15. Postmus PE, Berendsen HH, van Zandwijk N, Splinter TA, Burghouts JT, Bakker W. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol. 1987;23(9):1409-11.